All-in-One Prime Editing System for Efficient Generation and Isolation of Single Edited hiPSC Clones
Summary
Prime editing has emerged as the preferred gene-editing technique due to its versatility and precision in introducing genetic modifications such as single-base pair substitutions, insertions, and deletions without the need for double-strand breaks (DSBs) and a donor template. Thus, substantially reduces the likelihood of off-target effects that are generally produced when using the traditional CRISPR-Cas9 system. Here, we describe an in-depth protocol for the generation and isolation of prime-edited single human induced pluripotent stem cell (hiPSC) clones.
Keywords
Prime editing has emerged as the preferred gene-editing technique due to its versatility and precision in introducing genetic modifications such as single-base pair substitutions, insertions, and deletions without the need for double-strand breaks (DSBs) and a donor template. Thus, substantially reduces the likelihood of off-target effects that are generally produced when using the traditional CRISPR-Cas9 system. Here, we describe an in-depth protocol for the generation and isolation of prime-edited single human induced pluripotent stem cell (hiPSC) clones. In this example, we transfect a commercial hiPSC line with an all-in-one prime editor plasmid to install a pathogenic PRPH2 mutation using the PE3 approach.
Abstract from PubMed (PMID 43015546). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.
Related articles
Orthogonal ensemble and single-particle characterisation of antisense oligonucleotide lipid nanoparticles
Discover nanoLipid nanoparticle-based mRNA delivery system for cancer management
Molecular cancersiRNA-mediated mismatch repair disruption synergizes with oxaliplatin to restore immune surveillance in microsatellite-stable colorectal cancer
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
